Abstract:Glycogen storage disease type VI (GSD-VI; also known as Hers disease, liver phosphorylase deficiency) is caused by mutations in the gene coding for glycogen phosphorylase (PYGL) leading to a defect in the degradation of glycogen. Since there are only about 40 patients described in literature, our knowledge about the course of the disease is limited. In order to evaluate the long-term outcome of patients with GSD-VI, an observational retrospective case study of six patients was performed at the University Children's Hospital Zurich. The introduction of small, frequent meals as well as cornstarch has led to normal growth in all patients and to normalization of liver transaminases in most patients. After starting the dietary regimen, there were no signs of hypoglycemia. However, three of six patients showed persistent elevation of triglycerides. Further, we identified four novel pathogenic PYGL mutations and describe here their highly variable impact on phosphorylase function.Conclusions: After establishing the diagnosis, dietary treatment led to metabolic stability and to prevention of hypoglycemia. Molecular genetics added important information for the understanding of the clinical variability in this disease. While outcome was overall excellent in all patients, half of the patients showed persistent hypertriglyceridemia even after initiating treatment.<table class="a-plus-plus table default-table float-no id-taba"><tbody class="a-plus-plus tbody"><tr class="a-plus-plus row"><td class="a-plus-plus entry nameend-c2 namest-c1">What is Known:• Glycogen storage disease type VI (GSD-VI) is a metabolic disorder causing a defect in glycogen degradation. Dietary treatment normally leads to metabolic stability and prevention of hypoglycemia.• However, our knowledge about the natural course of patients with GSD-VI is limited.</td></tr><tr class="a-plus-plus row"><td class="a-plus-plus entry nameend-c2 namest-c1">What is New:• While outcome was overall excellent in all patients, half of the patients showed persistent hypertriglyceridemia even after initiating treatment.• Molecular genetics added important information for the understanding of the clinical variability in this disease.</td></tr></tbody></table>

Thymolipoma simulating cardiomegaly: a clinicopathological rarity.

Glycogen storage diseases with liver involvement: a literature review of GSD type 0, IV, VI, IX and XI

The Phenotypic and Genetic Spectrum of Glycogen Storage Disease Type VI

A Broad Characterization of Glycogen Storage Disease IV Patients: A Clinical, Genetic, and Histopathological Study

Glycogen storage disease type I: clinical and laboratory profile

Glycogen storage disease type VI: clinical course and molecular background

Glycogen storage diseases: New perspectives

Glycogen Storage Disease Type I and Bone: Clinical and Cellular Characterization

Neurological Characteristics of Pediatric Glycogen Storage Disease

Identification of the larval serum proteins as major fruit fly (Drosophila melanogaster) occupational allergens.

Genotypic and phenotypic features of 39 Chinese patients with glycogen storage diseases type I, VI, and IX

Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care

Glycogen storage disease type IX: High variability in clinical phenotype

Inflammatory bowel disease is associated with hidradenitis suppurativa: Results from a multicenter cross‐sectional study

Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0.

Reduced-size liver transplantation for glycogen storage disease.

Clinical and Laboratory Findings on Glycogen Storage Disease Type V: Results from a Retrospective Observational Study in a Tertiary Hospital

Update on glycogen storage disease: primary hepatic involvement

CNET: design of an RSFQ switching network for petaflops-scale computing

A case study of a liver transplant-treated patient with glycogen storage disease type Ia presenting with multiple inflammatory hepatic adenomas: an analysis of clinicopathologic and genetic data

Glycogen storage disease type III: a mixed-methods study to assess the burden of disease